Ernexa Therapeutics Inc. (ERNA)
Market Cap | 10.13M |
Revenue (ttm) | 582,000 |
Net Income (ttm) | -44.56M |
Shares Out | 52.24M |
EPS (ttm) | -3.26 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 153,017 |
Open | 0.1910 |
Previous Close | 0.1842 |
Day's Range | 0.1883 - 0.1960 |
52-Week Range | 0.1500 - 2.6300 |
Beta | 7.37 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | May 13, 2025 |
About ERNA
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. ... [Read more]
Financial Performance
In 2024, Ernexa Therapeutics's revenue was $582,000, an increase of 755.88% compared to the previous year's $68,000. Losses were -$44.56 million, 105.5% more than in 2023.
Financial StatementsNews

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
Conference attendees will get first look at new data that supports the potential of ERNA-101 to boost anti-tumor immunity in ovarian cancer Conference attendees will get first look at new data that su...

Ernexa Therapeutics Closes New Funding Round
Comes on the heels of company's rebranding and new strategic direction, advancing its lead program in ovarian cancer Comes on the heels of company's rebranding and new strategic direction, advancing i...

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
Meeting addressed progress and strategic direction for company's induced mesenchymal stem cell (iMSC) therapy programs Meeting addressed progress and strategic direction for company's induced mesenchy...

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
New data from proof-of-concept study provides roadmap for treatment of ovarian cancer.

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna's lead indication in ovarian cancer World-renowned researcher brings expertise in obstetr...

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) announced today that it has regained compliance with Nasdaq for continued listin...

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) today announced the successful completion of a comprehensive financial restructu...

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license an...

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs
The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic...

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a preclinical-stage biopharmaceutical company, committed to realizing the poten...

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engine...

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engine...

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engine...

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engin...

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engine...

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
mRNA cell engineering strategically targets genes to create novel and potentially superior product profiles for cell transplant therapy applications

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engi...

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engine...

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel
CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell enginee...

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Approach is potentially first iPS cell-derived multi-cell-type therapeutic strategy designed to mimic how the human immune system naturally fights disease

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics
Acquisition includes Exacis' entire pipeline of engineered cell therapy programs for hematologic and solid tumors

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million
CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engin...

Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board
Renowned scientist and serial entrepreneur Jeff Karp, Ph.D., brings deep research experience and industry knowledge that will help guide Eterna as it advances its mRNA cell engineering platform

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights
– Executed income generating license agreement with Lineage Cell Therapeutics to develop gene-edited induced pluripotent stem cell (iPSC)-derived therapies for multiple neurology indications